Placeholder Banner

Xoma to develop antibody for H1N1 and H5N1

September 24, 2009
XOMA Ltd. (Nasdaq:XOMA) is developing an antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to neutralize group 1 influenza A viruses, including H1N1 and H5N1. XOMA will conduct the program under a $2.2 million subcontract with SRI International of Menlo Park, California. The National Institute of Allergy and Infectious Diseases will fund the subcontract.

Read the release.